Study of MAP0010 in Asthmatic Children and Adolescents
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are to evaluate the efficacy, tolerability and pharmacokinetics
of 2 doses of MAP0010 (Unit Dose Budesonide) in asthmatic children/adolescents.
Phase:
Phase 2
Details
Lead Sponsor:
Allergan
Collaborator:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan